A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of the National Cancer Institute

• Publication date

  2005-10-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JNCI/DJI315PMID 16234567
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hepatic resection for hepatocellular carcinoma

  2005cited by this paper
• Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre

  2005cited by this paper
• Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

  2004cited by this paper
• Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy.

  2004cited by this paper
• Lamivudine for the prevention of hepatitis B virus reactivation in hbsag seropositive cancer patients undergoing cytotoxic chemotherapy

  2004cited by this paper
• Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma

  2004cited by this paper
• Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

  2004cited by this paper
• 7 Prognosis factors in patients with early-intermediate hepatocellular carcinoma (HCC) according to Okuda classification, cancer of the liver Italian Program (CLIP) and Barcelona Clinic Liver Cancer (BCLC) staging systems: results of a single Italian centre

  2003cited by this paper
• Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

  2002cited by this paper
• Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon‐alpha, doxorubicin and 5‐fluorouracil chemotherapy

  2002cited by this paper
• Hepatocellular carcinoma: is current therapy really altering outcome?

  2002cited by this paper
• Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

  2002cited by this paper
• Systemic therapy for hepatocellular carcinoma.

  2001cited by this paper
• Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors

  2000cited by this paper
• Microwave coagulation therapy for hepatocellular carcinoma.

  2000cited by this paper
• Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.

  1999cited by this paper
• Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial

  1999cited by this paper
• Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.

  1999cited by this paper
• Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode.

  1998cited by this paper
• [Chemotherapy of hepatocellular carcinoma].

  1998cited by this paper
• Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients.

  1998cited by this paper
• A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

  1998cited by this paper
• Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres.

  1998cited by this paper
• Cryosurgical ablation of hepatic tumors.

  1997cited by this paper
• Microwave coagulation therapy for hepatocellular carcinoma.

  1996cited by this paper
• Hepatocellular carcinoma in the United States: Prognostic features, treatment outcome, and survival

  1996cited by this paper
• Hepatic Resection for Hepatocellular Carcinoma An Audit of 343 Patients

  1995cited by this paper
• The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy.

  1994cited by this paper
• Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: A multivariate analysis of prognostic factors

  1994cited by this paper
• Recombinant interferon‐α in inoperable hepatocellular carcinoma: A randomized controlled trial

  1993cited by this paper
• Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.

  1993cited by this paper
• Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients

  1990cited by this paper
• Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites.

  1988cited by this paper
• Clinical trials in primary hepatocellular carcinoma: current status and future directions.

  1988cited by this paper
• A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: An ECOG study

  1987cited by this paper
• Significance of serum bilirubin level in response of hepatocellular carcinoma to doxorubicin.

  1986cited by this paper
• 4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma.

  1985cited by this paper
• Estimates of the worldwide frequency of twelve major cancers.

  1984cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1980cited by this paper
• Primary liver cancers in Japan

  1980cited by this paper
• Transection of the oesophagus for bleeding oesophageal varices

  1973cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• 2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione from Averrhoa carambola L. roots: Suppressing hepatocellular carcinoma progression through ROS accumulation and p53 pathway-mediated apoptosis.

  2025cites this paper
• One stone two birds: conjugation of graphene oxide with Rg3–doxorubicin reduces its toxicity and downregulates metallothionein expression for improved liver-targeted therapy

  2025cites this paper
• Response Rate Correlates with the Conversion Rate in Patients with Advanced Hepatocellular Carcinoma Treated with Systemic or Hepatic Artery Infusion Chemotherapy: A Systematic Review

  2025cites this paper
• Dual roles of USP1 in HELLS deubiquitination and SUMOylation drive EMT and FOLFOX-based chemoresistance

  2025cites this paper
• Light to Moderate Alcohol Consumption and Cancer Incidence: The Norwegian Women and Health Cohort Study

  2025cites this paper
• Alcohol Dehydrogenase 4‐Mediated Retinol Metabolism Inhibits Hepatocellular Carcinoma Progression Through Inhibiting the Wnt/β‐Catenin Pathway

  2025cites this paper
• The epigenetic basis of hepatocellular carcinoma – mechanisms and potential directions for biomarkers and therapeutics

  2025cites this paper
• Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma

  2024cites this paper
• Cetylpyridinium chloride inhibits hepatocellular carcinoma growth and metastasis through regulating epithelial-mesenchymal transition and apoptosis

  2024cites this paper
• Re-exploration of immunotherapy targeting EMT of hepatocellular carcinoma: Starting from the NF-κB pathway.

  2024cites this paper
• A new chemotherapy strategy for advanced hepatocellular carcinoma with exrahepatic metastasis: predictors of long-term survival

  2024cites this paper
• Functional combination of resveratrol and tamoxifen to overcome tamoxifen‐resistance in breast cancer cells

  2024cites this paper
• Autophagy in cancer immunotherapy: Perspective on immune evasion and cell death interactions.

  2024cites this paper
• Plasma-derived extracellular matrix for xenofree and cost-effective organoid modeling for hepatocellular carcinoma

  2024cites this paper
• Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.

  2024cites this paper
• Precision Oncology in Hepatopancreatobiliary Cancer Surgery.

  2024cites this paper
• Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis

  2024cites this paper
• Integrated imaging probe and bispecific antibody development enables in vivo targeting of glypican-3-expressing hepatocellular carcinoma.

  2024cites this paper
• Platycodin D2 enhances P21/CyclinA2-mediated senescence of HCC cells by regulating NIX-induced mitophagy

  2024cites this paper
• TFCP2 as a therapeutic nexus: unveiling molecular signatures in cancer

  2024cites this paper
• Dendrobium nobile active ingredient Dendrobin A against hepatocellular carcinoma via inhibiting nuclear factor kappa-B signaling.

  2024cites this paper
• PH-sensitive adriamycin hydrochloride and oxaliplatin dual-loaded microspheres synergistically enhance local injections effect of hepatocellular carcinoma

  2024cites this paper
• Delta-radiomics Analysis Based on Multi-phase Contrast-enhanced MRI to Predict Early Recurrence in Hepatocellular Carcinoma After Percutaneous Thermal Ablation.

  2024cites this paper
• Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor.

  2024cites this paper
• Insights on Anticancer Activities, Associated Phytochemicals and Potential Molecular Mechanisms of Quisqualis indica: A Mini Review

  2023cites this paper
• The mechanism of high-mobility group box-1 protein and its bidirectional regulation in tumors

  2023cites this paper
• Orthogonally Engineered Albumin with Attenuated Macrophage Phagocytosis for the Targeted Visualization and Phototherapy of Liver Cancer.

  2023cites this paper
• [^177Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy

  2023cites this paper
• Adjuvant and neoadjuvant therapies for hepatocellular carcinoma.

  2023cites this paper
• Principle active metabolites of Pinus morrisonicola Hayata synergistically inhibit cell proliferation and autophagy to elevate apoptosis in hepatocellular carcinoma cells

  2023cites this paper
• Cellular and Molecular Biology of Cancer Stem Cells of Hepatocellular Carcinoma

  2023cites this paper
• Periplocin inhibits hepatocellular carcinoma progression and reduces the recruitment of MDSCs through AKT/NF-κB pathway.

  2023cites this paper
• Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma

  2023cites this paper
• Brazilian Landscape of Hepatocellular Carcinoma

  2023cites this paper
• Integrated machine learning and bioinformatic analyses used to construct a copper-induced cell death-related classifier for prognosis and immunotherapeutic response of hepatocellular carcinoma patients

  2023cites this paper
• Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

  2023cites this paper
• The functions and molecular mechanisms of Tribbles homolog 3 (TRIB3) implicated in the pathophysiology of cancer.

  2023cites this paper
• Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective

  2023cites this paper
• Successful conversion therapy for unresectable hepatocellular carcinoma is getting closer: A systematic review and meta-analysis

  2022influential citation
• A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma

  2022cites this paper
• Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions.

  2022cites this paper
• A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study

  2022influential citation
• Design, Synthesis, and Biological Evaluation of Novel Evodiamine Derivatives as Potential Antihepatocellular Carcinoma Agents.

  2022cites this paper
• Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma

  2022cites this paper
• A hepatocellularis carcinoma komplex kezelése.

  2022cites this paper
• Ultrastructural analysis of zinc oxide nanospheres enhances anti-tumor efficacy against Hepatoma

  2022cites this paper
• Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer

  2022cites this paper
• Use of chemotherapy to treat hepatocellular carcinoma.

  2022cites this paper
• Meet the Honorary Senior Advisor

  2022cites this paper
• PPARγ signaling in hepatocarcinogenesis: Mechanistic insights for cellular reprogramming and therapeutic implications.

  2022cites this paper
• diTFPP, a Phenoxyphenol, Sensitizes Hepatocellular Carcinoma Cells to C2-Ceramide-Induced Autophagic Stress by Increasing Oxidative Stress and ER Stress Accompanied by LAMP2 Hypoglycosylation

  2022cites this paper
• Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook

  2022cites this paper
• Curcumin Boosts Natural Killer Cell-Based Immunotherapy in Impeding Progression of Hepatocellular Carcinoma Through Androgen Receptor/UL16 Binding Protein-2 Signal

  2022cites this paper
• Intratumoral Pi deprivation benefits chemoembolization therapy via increased accumulation of intracellular doxorubicin

  2022cites this paper
• TKIs beyond immunotherapy predict improved survival in advanced HCC

  2022cites this paper
• A radiomics-based model can predict recurrence-free survival of hepatocellular carcinoma after curative ablation.

  2022cites this paper
• Purified PTEN-Long Induces Liver Cancer Cells to Undergo Autophagy and Apoptosis

  2022cites this paper
• Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis

  2021cites this paper
• The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers.

  2021cites this paper
• SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback.

  2021cites this paper
• HMGB1 Promotes Resistance to Doxorubicin in Human Hepatocellular Carcinoma Cells by Inducing Autophagy via the AMPK/mTOR Signaling Pathway

  2021cites this paper
• A new triazolothiadiazine derivative inhibits stemness and induces cell death in HCC by oxidative stress dependent JNK pathway activation

  2021cites this paper
• Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities

  2021cites this paper
• Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma

  2021cites this paper
• Evolution of systemic treatment for advanced hepatocellular carcinoma

  2021cites this paper
• PLEKHA8P1 Promotes Tumor Progression and Indicates Poor Prognosis of Liver Cancer

  2021cites this paper
• Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials

  2021cites this paper
• Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC)

  2021cites this paper
• Crizotinib and Doxorubicin Cooperatively Reduces Drug Resistance by Mitigating MDR1 to Increase Hepatocellular Carcinoma Cells Death

  2021cites this paper
• Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment

  2021influential citation
• Adamantane-linked isothiourea derivatives suppress the growth of experimental hepatocellular carcinoma via inhibition of TLR4-MyD88-NF-κB signaling.

  2021cites this paper
• Enhancing the chemosensitivity of HepG2 cells towards cisplatin by organoselenium pseudopeptides.

  2021cites this paper
• Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors

  2020cites this paper
• BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA.

  2020cites this paper
• Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

  2020cites this paper
• CMAR_A_280631 12239..12248

  2020influential citation
• INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus

  2020cites this paper
• Green tea and black tea inhibit proliferation and migration of HepG2 cells via the PI3K/Akt and MMPs signalling pathway.

  2020cites this paper
• Lipoproteins-nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects.

  2020cites this paper
• Digitoxin inhibits proliferation of multidrug-resistant HepG2 cells through G2/M cell cycle arrest and apoptosis

  2020cites this paper
• Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.

  2020cites this paper
• Liver and Bile Duct Cancer

  2020cites this paper
• Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries

  2020cites this paper
• 1β-OH-arenobufagin induces mitochondrial apoptosis in hepatocellular carcinoma through the suppression of mTOR signaling pathway.

  2020cites this paper
• Doxorubicin for the treatment of hepatocellular carcinoma: GAME OVER!

  2020cites this paper
• Novel molecular targets in hepatocellular carcinoma

  2020cites this paper
• A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma

  2020cites this paper
• Hydroxysafflor yellow A sensitizes ovarian cancer cells to chemotherapeutic agent by decreasing WSB1 expression

  2019cites this paper
• MiR-204 inhibits hepatocellular cancer drug resistance and metastasis through targeting NUAK1.

  2019cites this paper
• The future is now: beyond first line systemic therapy in hepatocellular carcinoma

  2019cites this paper
• Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma

  2019cites this paper
• The Current Landscape of Systemic Therapies for Advanced Hepatocellular Carcinoma

  2019cites this paper
• Transferrin Modified Nano-liposome Co-delivery Strategies for Enhancing the Cancer Therapy.

  2019cites this paper
• Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

  2019cites this paper
• An Analysis for Survival Predictors for Patients with Hepatocellular Carcinoma Who Failed to Sorafenib Treatment in Pre-regorafenib Era

  2019cites this paper
• Molecular therapies and precision medicine for hepatocellular carcinoma 1

  2019cites this paper
• Liver Cancer

  2019cites this paper
• Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.

  2019cites this paper
• Consistency in biomarkers expression between matched tissue microarray cores from primary gallblader and ovarian cancers

  2019cites this paper
• Autophagy: A novel mechanism of chemoresistance in cancers.

  2019cites this paper